A dialysis fluid containing human albumin and preparation method thereof

A human albumin-based dialysate with osmotic regulators, buffers, and stabilizers addresses biocompatibility and complexity issues, enhancing ultrafiltration and simplifying use, thus improving dialysis efficacy.

CN118649228BActive Publication Date: 2024-12-06TONGHUA ANRATE BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411132546.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-12-06
Estimated Expiration
2044-08-19

AI Technical Summary

Technical Problem

Existing dialysates have poor biocompatibility, require complex preparation and usage processes, and often use sugars as main raw materials, which complicate storage and operation.

Method used

A dialysate formulation using human albumin as the main component, supplemented with osmotic pressure regulators, buffers, stabilizers, and antioxidants, with a simplified preparation method involving sterilization, mixing, and packaging steps.

Benefits of technology

The dialysate exhibits improved biocompatibility, enhanced ultrafiltration function, and simplified storage and usage, offering better therapeutic efficacy compared to sugar-based dialysates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention relates to the field of biomedicine, and in particular to a dialysate containing human albumin and a preparation method thereof. The dialysate of the present invention comprises human albumin, an osmotic pressure regulator, a buffer, and a stabilizer. The human albumin content is 5% to 25% (w / w). The present invention provides a low-cost, high-quality dialysate prescription and preparation process, which has good biocompatibility, can avoid the risk of side effects caused by the patient during the treatment process, and plays a key role in the removal of metabolites such as bilirubin and creatinine in patients with renal failure.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to a dialysate containing human albumin and a preparation method thereof. Background Art

[0002] With the rapid development of medical technology, the important position of human albumin in medical clinical practice is increasingly recognized by the biomedical field. This is due to its ability to scavenge free radicals and increase the solubility of long-chain fatty acids; it can also be used as a delivery system for anti-tumor drugs.

[0003] Human serum albumin (HSA) is the protein with the highest content in plasma, accounting for about half of the total plasma protein. Human serum albumin is a monomeric protein produced by the liver. Mature human serum albumin contains 585 amino acid residues and has a molecular weight of 66KD. Human serum albumin products are therapeutic drugs extracted from human plasma and have many important physiological functions: 1. Maintaining plasma colloidal osmotic pressure and regulating body fluid distribution; 2. Having ligand binding ability, it can store and transport endogenous and exogenous substances; 3. Nutritional effect. It is mainly used to treat: 1. Shock caused by blood loss and trauma, 2. Increased intracranial pressure caused by cerebral edema and injury; 3. Edema or ascites caused by cirrhosis and kidney disease. Patent CN108144042B discloses a method for preparing a peritoneal dialysis fluid containing a glucose polymer, which can improve the irritation to the dialysis site in a low pH environment; Patent CN117883373 discloses a method for preparing an icodextrin peritoneal dialysis fluid, which improves the therapeutic effect of the dialysis fluid by adjusting the dissolution temperature and dissolution time. The above documents all use monosaccharides or polysaccharides as the raw materials of the dialysis fluid, which have poor biocompatibility and a relatively complicated production process. At the same time, the existing peritoneal dialysis fluid with sugars as the main raw material is often divided into A liquid and B liquid, which need to be stored separately and mixed in proportion when used, and the operation process is complicated.

[0004] Currently, there is an urgent need for a dialysate that has good biocompatibility, is simple to prepare, and is easy to use. Summary of the invention

[0005] To solve the above problems, the present invention provides a dialysate containing human albumin and a preparation method thereof. Improving the biocompatibility and effectiveness of the dialysate containing human albumin is of great significance for toxin removal and health improvement.

[0006] In one aspect, the present invention provides a dialysate containing human albumin, comprising: human albumin, an osmotic pressure regulator, a buffer and a stabilizer, wherein the mass fraction of human albumin is 5% to 25% (w / w); the mass fraction of the osmotic pressure regulator is 0.2% to 0.8% (w / w); the mass fraction of the buffer is 0.01% to 0.1% (w / w); and the mass fraction of the stabilizer is 0.2% to 1% (w / w).

[0007] In an embodiment of the present invention, the human albumin includes one or more of blood-derived human albumin and recombinant human albumin. Preferably, the human albumin is recombinant human albumin. Among them, blood-derived human albumin refers to albumin separated and purified from healthy human blood, plasma or specific immune plasma; recombinant human albumin refers to albumin prepared by recombinant DNA technology for the treatment and prevention of diseases.

[0008] In an embodiment of the present invention, the osmotic pressure regulator includes sodium chloride, and the mass fraction of the osmotic pressure regulator is 0.2%~0.8% (w / w). Preferably, the osmotic pressure regulator may also include one or more of calcium chloride and magnesium chloride, wherein the mass fraction of calcium chloride is 0.01~0.03% (w / w), and the mass fraction of magnesium chloride is 0.002~0.006% (w / w).

[0009] In an embodiment of the present invention, the buffer includes one or more of acetate and lactate, bicarbonate, pyruvate, and citrate, and the mass fraction of the buffer is 0.01% to 0.1% (w / w). Preferably, the buffer is lactate, and more preferably, the buffer is sodium lactate.

[0010] In an embodiment of the present invention, the stabilizer includes one or more of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and poloxamer 407, and the mass fraction of the stabilizer is 0.2% to 1% (w / w). Preferably, the stabilizer is a polysorbate series, and more preferably, the stabilizer is polysorbate 80.

[0011] In an embodiment of the present invention, the dialysate further comprises an antioxidant, and the mass fraction of the antioxidant is 0.01-2.3% (w / w). The antioxidant comprises one or more of sodium sulfite, sodium bisulfite and glycine. Preferably, the antioxidant is sodium sulfite and glycine, wherein the content of sodium sulfite is 0.01%-0.1% (w / w), and the content of glycine is 1%-2.2% (w / w).

[0012] In a preferred embodiment of the present invention, the permeate comprises: 5%~25% (w / w) human albumin; 0.01%~0.1% (w / w) sodium lactate; 0.2%~0.8% (w / w) sodium chloride; 1%~2.2% (w / w) glycine; 0.2%~1% (w / w) polysorbate 80; and 0.01%~0.1% (w / w) sodium sulfite.

[0013] In an embodiment of the present invention, the dialysate pH value of the present invention is 6.4-7.4, and the osmotic pressure is 300-380 mOsm / Kg.

[0014] A second aspect of the present invention provides a method for preparing a dialysate containing human albumin, comprising the following steps:

[0015] 1) Sterilization: sterilize the salt components in each component at high temperature, temperature: 115℃~121℃, sterilization time: 15~60min; in the embodiment of the present invention, the salt components include sulfite, bisulfite, chloride, acetate and lactate, bicarbonate, pyruvate, citrate or more, preferably, the salt components include sodium lactate, sodium chloride, sodium sulfite. In the preferred embodiment of the present invention, the sterilization temperature is 121℃, and the sterilization time is 30min.

[0016] 2) Preparation: Add each component in a mass fraction ratio into sterilized water for injection, dissolve and stir evenly, and sterilize and filter with a filter of a specific pore size; in the embodiment of the present invention, each component is added per 1000ml, and the mass of each component is: human albumin: 50~250g, sodium lactate: 0.1~1.0mg, sodium chloride: 2~8mg, glycine: 10~22mg, polysorbate 80: 2~10mg, sodium sulfite: 0.1~1.0mg, and the rest is water for injection. In the embodiment of the present invention, the pore size of the filter is 0.45µm and 0.22µm respectively.

[0017] 3) Filling: Under a clean bench, fill the filtrate obtained in step 2) into a medical dialysis bag, put the filled dialysis bag into an outer bag with a high barrier, evacuate for 0.5-2 minutes and fill with nitrogen for 1-10 minutes, and package to obtain the dialysate. In an embodiment of the present invention, the medical dialysis bag in step 3) is made of non-PVC material.

[0018] The beneficial effects of the present invention include but are not limited to:

[0019] 1. The present invention provides a dialysate containing human albumin, which uses human albumin as the main raw material. Compared with the existing dialysate using carbohydrates as the main raw material, the dialysate has simpler components, better biocompatibility, increased ultrafiltration function, and enhanced dialysis effect, thereby achieving a therapeutic effect.

[0020] 2. The dialysate of the present invention is easy to store and does not need to be stored separately according to pH value or to prevent reactions between components. It does not need to be mixed according to a ratio when used, and is easy to operate.

[0021] 3. The present invention also provides a method for preparing a dialysate containing human albumin, which has a simple production process and has high application prospects. DETAILED DESCRIPTION

[0022] The present invention is further described in detail below through specific implementation modes, but it is only used to help understand the present invention so that professionals in the field can implement or use the present invention, and does not constitute any limitation to the present invention.

[0023] Definition: Hematogenous human albumin refers to albumin separated and purified from healthy human blood, plasma or specific immune plasma;

[0024] Recombinant human albumin refers to albumin prepared using recombinant DNA technology for treatment and prevention.

[0025] Source of materials: Recombinant human albumin: produced by Tonghua Anrui Biopharmaceutical Co., Ltd., product number: ART101S;

[0026] Blood-derived human albumin: purchased from Guangdong Weilun Biopharmaceutical Co., Ltd.;

[0027] SD rats: purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.;

[0028] Glucose peritoneal dialysis fluid: purchased from Huaren Pharmaceutical Co., Ltd. and Shijiazhuang Siyao Co., Ltd.;

[0029] Unless otherwise specified, other reagents and instruments used were commercially available.

[0030] Example 1 Preparation of Dialysate

[0031] The composition of each 1000 ml of dialysate by weight is as shown in Table 1. The rest is sterile water for injection.

[0032] Table 1 Composition of various dialysates containing human albumin

[0033]

[0034] Table 1 continued

[0035]

[0036] The specific steps for preparing 1000 ml of dialysate are as follows:

[0037] 1) Use a sterilized grade A measuring cylinder to measure 1000 ml of sterilized water for injection;

[0038] 2) According to the composition of each formula, weigh the corresponding mass of various salt components for high temperature sterilization at 121°C for 30 minutes;

[0039] 3) According to the formula, weigh: human albumin dry powder, glycine, polysorbate 80, and other non-salt components and the sterilized salt components obtained in 2) into a sterilized beaker, add 1000 ml of sterilized water for injection, dissolve, stir evenly, and filter through a 0.45 μm filter membrane to remove particles, and then use a 0.22 μm filter membrane to sterilize and filter to obtain a filtrate. Fill the filtrate into a medical dialysis bag in an ultra-clean workbench, put the filled medical dialysis bag into an outer bag with a high barrier, evacuate for 0.5-2 min and fill with nitrogen for 1-10 min, and seal to obtain a dialysate containing human albumin of the corresponding serial number.

[0040] Example 2 Peritoneal influence test

[0041] Experimental animals: SD rats, male, weighing 200±10g, a total of 280 rats, were randomly divided into 56 groups, 5 rats in each group, of which groups 1 to 49 were injected with dialysate containing human albumin of formula No. 1 to 49 in Table 1. Groups 50 to 56 were the control group, and the specific dialysate information is shown in Table 2.

[0042] Table 2 Dialysate information of the control group

[0043]

[0044] Pharmacodynamics experiment of recombinant human albumin and blood-derived human albumin dialysate

[0045] The corresponding dialysate (100 ml / kg) was injected intraperitoneally into the SD rats of each group once a day for 6 consecutive weeks until the dialysis was terminated.

[0046] Determination of ultrafiltration volume

[0047] Within 24 hours after the end of ultradialysis, each SD rat in groups 1 to 56 was anesthetized and intraperitoneally injected with 0.9% saline (100 mL / kg). Four hours later, the abdominal wall was cut open along the white line of the abdomen, the peritoneal fluid was measured, and the volume of the total dialysis effluent (ml) was measured. The experimental results are shown in Table 3.

[0048] Ultrafiltration volume: Ultrafiltration volume = final water output - 25mL.

[0049] Determination of bilirubin, creatinine concentration and urea nitrogen content

[0050] Blood samples and peritoneal fluid were collected from each SD rat at 0h and 4h after dialysis. The blood samples were centrifuged at 4000rpm / min for 15min, and the peritoneal dialysis fluid samples were centrifuged at 2000rpm / min for 5min. The bilirubin, creatinine and urea nitrogen concentrations in the effluent and plasma were measured. The experimental results are shown in Table 3.

[0051] Bilirubin clearance = [(total dialysate outflow volume ml) x (ratio of bilirubin concentration in dialysate outflow to bilirubin concentration in plasma)];

[0052] Creatinine clearance = [(total volume of dialysate outflow, ml) x (ratio of creatinine concentration in dialysate outflow to creatinine concentration in plasma)];

[0053] Urea nitrogen clearance = [(total volume of dialysate outflow, ml) x (ratio of urea nitrogen concentration in dialysate outflow to urea nitrogen concentration in plasma)].

[0054] Table 3 Results of ultrafiltration test and determination of bilirubin, creatinine concentration and urea nitrogen content of dialysate in each group

[0055]

[0056] As can be seen from Table 3, the ultrafiltration volume of SD rats in the experimental results of the dialysate containing recombinant human albumin of the present invention and the experimental groups (Groups 1 to 49) of the dialysate containing hematogenous human albumin are significantly higher than those in Group 50 dialyzed with 0.9% saline and the control group (Groups 51 to 56) using commercially available sugar-containing peritoneal dialysis fluid. The ultrafiltration volume results of the recombinant human albumin dialysate of the present invention are similar to those of the hematogenous human albumin dialysate, indicating that the recombinant human albumin dialysate has the same efficacy as the hematogenous human albumin dialysate and is closer to normal physiological conditions.

[0057] Table 3 Comparison of experimental data of bilirubin, creatinine concentration and urea nitrogen content in each group of rats after 6 weeks shows:

[0058] The clearance capabilities of SD rats in groups 1 to 49 that were dialyzed with the human albumin-containing dialysate described in the present invention were higher than those of rats in groups 50 that were dialyzed with 0.9% saline dialysate and rats in groups 51 to 56 that were dialyzed with carbohydrate dialysate. The dialysate made with our company's recombinant human albumin performed better in removing toxins than the dialysate made with blood-derived human albumin.

[0059] The production method of the invention has simple process, convenient operation and easy commercial production. The prepared product is a dialysate containing human albumin, which is suitable for patients with renal failure. Compared with the dialysate mainly composed of sugars, it has better clearance ability, good biocompatibility and efficacy, and has broad development prospects.

[0060] The above description is only an embodiment of the present invention. The protection scope of the present invention is not limited by these specific embodiments, but is determined by the claims of the present invention. For those skilled in the art, the present invention may have various changes and variations. Any modification, equivalent substitution, improvement, etc. made within the technical ideas and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A peritoneal dialysis fluid containing human albumin, It is characterized in that The peritoneal dialysis fluid comprises: human albumin, an osmotic pressure regulator, a buffer and a stabilizer, wherein the mass fractions of the components of the peritoneal dialysis fluid are as follows: The mass fraction of human albumin is 5%~25% (w / w); The mass fraction of the osmotic pressure regulator is 0.0002% to 0.0008% (w / w), and the osmotic pressure regulator includes sodium chloride; The mass fraction of the buffer is 0.00001% to 0.0001% (w / w), and the buffer is one of sodium acetate, sodium lactate, sodium bicarbonate, sodium pyruvate, and sodium citrate; The mass fraction of the stabilizer is 0.0002% to 0.0001% (w / w), and the stabilizer is one of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and poloxamer 407.

2. The peritoneal dialysis fluid according to claim 1, It is characterized in that The human albumin is hematogenous human albumin or recombinant human albumin.

3. The peritoneal dialysis fluid according to claim 1, It is characterized in that The osmotic pressure regulator also includes calcium chloride or magnesium chloride.

4. The peritoneal dialysis solution according to claim 1, It is characterized in that The peritoneal dialysis fluid also includes an antioxidant, which is glycine and sodium sulfite, and the mass fraction of the antioxidant is 0.00001% to 0.0023% (w / w).

5. The peritoneal dialysis fluid according to claim 1, It is characterized in that The peritoneal dialysis fluid includes: 5%~25% (w / w) human albumin; 0.00001%~0.0001% (w / w) sodium lactate; 0.0002%~0.0008% (w / w) sodium chloride; 0.001%~0.0022% (w / w) glycine; 0.0002%~0.001% (w / w) polysorbate 80; and 0.00001%~0.0001% (w / w) sodium sulfite.

6. A method for preparing the peritoneal dialysis fluid according to any one of claims 1 to 5, It is characterized in that The steps include: 1) Sterilization: sterilize the salt components at high temperature, temperature: 115℃~121℃, sterilization time: 15~60min; 2) Preparation: Add each component according to the mass fraction ratio into sterilized water for injection, dissolve and stir evenly, and sterilize and filter with filters with pore sizes of 0.45µm and 0.22µm; 3) Filling: Under a clean bench, the filtrate obtained in step 2) is filled into a medical dialysis bag, and the filled dialysis bag is placed into an outer bag with a high barrier, vacuumed for 0.5 to 2 minutes and filled with nitrogen for 1 to 10 minutes, and packaged to obtain the peritoneal dialysis solution.

7. The method according to claim 6, It is characterized in that The medical dialysis bag described in step 3) is a dialysis bag made of non-PVC material.